B U Mueller

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi The infant with a vascular tumor
    B U Mueller
    Department of Medicine, Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
    Semin Perinatol 23:332-40. 1999
  2. ncbi Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children
    B U Mueller
    Pediatric Branch and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 42:3187-92. 1998
  3. ncbi Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing
    B U Mueller
    Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 42:1815-8. 1998
  4. ncbi Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS
    C Chougnet
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 184:201-5. 2001
  5. ncbi Kinetics of HIV-1 RNA concentration changes in pediatric patients
    S L Zeichner
    HIV and AIDS Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Pathobiology 64:289-94. 1996
  6. ncbi Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy
    M A Polis
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10, Room 11C103, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Lancet 358:1760-5. 2001
  7. ncbi Cytomegalovirus infection in children with human immunodeficiency virus infection
    B J Kitchen
    Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Pediatr Infect Dis J 16:358-63. 1997
  8. ncbi Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer Institute
    M O Granovsky
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 16:1729-35. 1998
  9. ncbi Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine
    S Jankelevich
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 183:1116-20. 2001
  10. ncbi HIV-associated malignancies in children
    B U Mueller
    Department of Pediatrics, Harvard Medical School, Children s Hospital, Boston, Massachusetts, USA
    AIDS Patient Care STDS 13:527-33. 1999

Collaborators

Detail Information

Publications13

  1. ncbi The infant with a vascular tumor
    B U Mueller
    Department of Medicine, Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
    Semin Perinatol 23:332-40. 1999
    ..Vascular lesions should be biopsied if there is any suspicion of malignancy...
  2. ncbi Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children
    B U Mueller
    Pediatric Branch and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 42:3187-92. 1998
    ..A limited-sampling strategy was developed to estimate the area under the concentration-time curve for concentrations in serum at 2 and 6 h...
  3. ncbi Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing
    B U Mueller
    Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 42:1815-8. 1998
    ..The pharmacokinetic profile of KNI-272 may limit the drug's efficacy in vivo. It appears that KNI-272 will play a limited role in the treatment of HIV-infected children...
  4. ncbi Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS
    C Chougnet
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 184:201-5. 2001
    ..These findings suggest that long-term nonsuppressive antiretroviral therapy can induce limited improvement in immune function in pediatric AIDS patients and that the effect of suppressive treatments should be investigated...
  5. ncbi Kinetics of HIV-1 RNA concentration changes in pediatric patients
    S L Zeichner
    HIV and AIDS Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Pathobiology 64:289-94. 1996
    ..These findings may have implications for understanding HIV-1 pathogenesis and the development of therapeutic protocols...
  6. ncbi Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy
    M A Polis
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10, Room 11C103, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Lancet 358:1760-5. 2001
    ..75 or 1.00 log, respectively. We investigated the possibility of assessing drug efficacy from measurements of plasma HIV-1 concentrations made during the first week on therapy...
  7. ncbi Cytomegalovirus infection in children with human immunodeficiency virus infection
    B J Kitchen
    Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Pediatr Infect Dis J 16:358-63. 1997
    ..To determine retrospectively the prevalence of positive cytomegalovirus (CMV) cultures in pediatric patients with human immunodeficiency virus infection...
  8. ncbi Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer Institute
    M O Granovsky
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 16:1729-35. 1998
    ..To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors...
  9. ncbi Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine
    S Jankelevich
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 183:1116-20. 2001
    ..CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression...
  10. ncbi HIV-associated malignancies in children
    B U Mueller
    Department of Pediatrics, Harvard Medical School, Children s Hospital, Boston, Massachusetts, USA
    AIDS Patient Care STDS 13:527-33. 1999
    ..Such regimens may be complicated, however, by multiple HIV-associated organ dysfunctions, drug interactions, and infectious complications secondary to severe immunosuppression...
  11. ncbi Cancers in children infected with the human immunodeficiency virus
    B U Mueller
    Harvard Medical School, Hunnewell Children s Hospital, Boston, Massachusetts 02115, USA
    Oncologist 4:309-17. 1999
    ..This article provides an overview of epidemiology and clinical and pathological presentations, as well as preliminary data regarding treatment options in children with HIV-associated malignancies...
  12. ncbi Prevention of red cell dehydration: a possible new treatment for sickle cell disease
    B U Mueller
    Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Pediatr Pathol Mol Med 20:15-25. 2001
    ..In this brief review, we discuss the pathophysiologic background and explore some new treatment options to prevent vaso-occlusive crises or other problems in this patient population...
  13. ncbi Chemokine gene expression and clonal analysis of B cells in tissues involved by lymphoid interstitial pneumonitis from HIV-infected pediatric patients
    J Teruya-Feldstein
    Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mod Pathol 14:929-36. 2001
    ..In addition, LIP may represent an early stage of MALT lymphoma or an immunologic response to a chronic antigenic stimulus that may provide a milieu or microenvironment for the evolution of a monoclonal B-cell population...